Prosecution Insights
Last updated: November 04, 2026
Application No. 19/064,348

COMPOSITIONS AND METHODS TO MODIFY CELLS FOR THERAPEUTIC OBJECTIVES

Non-Final OA §102§103§DOUBLEPATENT
Filed
Feb 26, 2025
Priority
Mar 14, 2013 — provisional 61/785,907 +4 more
Examiner
LEONARD, ARTHUR S
Art Unit
1631
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Fred Hutchison Cancer Center
OA Round
1 (Non-Final)
50%
Grant Probability
Moderate
1-2
OA Rounds
1y 9m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 50% of resolved cases
50%
Career Allowance Rate
264 granted / 523 resolved
-9.5% vs TC avg
Strong +50% interview lift
Without
With
+50.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
53 currently pending
Career history
598
Total Applications
across all art units

Statute-Specific Performance

§101
3.6%
-36.4% vs TC avg
§103
42.9%
+2.9% vs TC avg
§102
15.4%
-24.6% vs TC avg
§112
22.5%
-17.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 523 resolved cases

Office Action

§102 §103 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claim status Claims 43-62 are pending Claims 43-62 are under examination Priority This application is a continuation of U.S. Patent Application No. 16/510,646, filed on July 12, 2019, which is a continuation of U.S. Patent Application No. 15/672, 106, filed August 8, 2017, now U.S. Patent No. 10,392,446, which is a continuation of U.S. Patent Application No.14/776,661, filed September 14, 2015, which is a U.S. National Phase Application based on International Patent Application No. PCT/US2014/029137, filed March 14, 2014, which claims priority to U.S. Provisional Patent Application No. 61/785,907, filed March 14, 2013. .Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, or 365(c) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 119(e) as follows: The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of the first paragraph of 35 U.S.C. 112. See Transco Products, Inc. v. Performance Contracting, Inc., 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994). The disclosure of the prior-filed application, Application No. 61/785,907, fails to provide adequate support or enablement in the manner provided by the first paragraph of 35 U.S.C. 112 for one or more claims of this application. Review of the application No. 61/785,907 did not reveal support for a single chain variable fragment (scFv) extending from the surface of the nanoparticle. Thus, instant claims are being given the filing date of 3/14/2014. Information Disclosure Statement The information disclosure statements (IDS) submitted on 5/06/2025, 4/06/2026, 7/23/2026 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner. However, Applicant is reminded that the listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered. Claim Objections Claim 55 is objected to because of the following informalities: the abbreviation “NLS” should be introduced in Claim 53. Appropriate correction is required. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 43-44, 53, 55-59 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Ashley et al., (US2015/0272885, filed 10/12/2012, published 10/01/2015). With respect to claim 43, Ashley teaches a synthetic nanocarrier comprising [AltContent: textbox ([img-media_image1.png])]A mesoporous silica nanoparticle (MSNP) core coated in a lipid bilayer; A scFv extending from the surface of the nanoparticle; A viral-specific siRNA within the pores of the nanoparticle ([0090, 0551, 0553], see Fig 1X6 adjacent). In regard to claim 44, as state supra, teaches a “lipid bilayer” surrounds the MSNP core. In regard to claim 53, Ashley teaches the nanocarrier further comprises an endosomal escape agent on the surface of the nanocarrier, and NLS attached to the cargo within the pores of the MSNP [0551]. In regard to claim 55, Ashley teaches the NLS is the SV40 peptide PKKKRKV, which is identical to SEQ ID NO:51 [0190]. In regard to claim 56, as shown supra, the nanocarrier is spherical. In regard to claims 57-59, Ashley teaches the nanocarrier is with a pharmaceutically acceptable carrier formulated as an aqueous solution for intravenous injection [0039, 0222-0226]. Accordingly, Ashley anticipates instant claims. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 47 and 60-63 are rejected under 35 U.S.C. 103 as being unpatentable over Ashley et al., (US2015/0272885, filed 10/12/2012, published 10/01/2015) in view of Chen et al. (Mol Therapy, 2010, 18(9):1650-1656) As stated supra, Ashley teaches a nanocarrier comprising (i) a lipid coated MSNP; (ii) a ScFv targeting ligand, (iii) a polynucleotide within the pores of the MSNP. In regard to claims 47 and 60, in an alternative embodiment, Ashley teaches polynucleotide is a plasmid DNA packaged with histones, and the resulting complex is modified with a NLS prior to being loaded into the silica core ([0185, 235]) Furthermore, in regard to claims 60-61, Ashley teaches that the plasmid can encode shRNA that encode anti-cancer genes that induced growth arrest and apoptosis [0185, 0235], and goes on to suggest targeting bcl-2 [0056, 0261], Note that instant claims do not require a full-length anti-cancer gene to be expressed. Furthermore, although Ashley does not reduce to practice a plasmid encoded anti-bcl-2 shRNA, she indicates that this was an obvious modification because siRNA-mediated RNAi is transient and only last for days, while plasmid encoded shRNA lasts for weeks [0470]. In regard to claim 62, Ashley teaches that nanocarrier composition further comprises an anti-cancer drug, such as taxol [0056, 0261]. MPEP 2144.06 states "It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art." In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980) (citations omitted). However, although Ashley teaches treating cancers such as melanomas [0191], she is silent to an scFv that targets cancer cells for the expression of the plasmid encoded shRNA. Nevertheless, Ashley cites the prior art of Chen (2000) [0352, 0450] Chen teaches a lipid coated nanoparticle comprising an scFv on its surface that targets human melanoma (Abstract, Methods, p. 1655, 4th para.) Accordingly, it would have been prima facie obvious to one of ordinary skill in the art at the time of filing to prepare as taught by prepare the scFv targeted nanocarrier for the treatments of cancers such as melanoma as taught by Ashley and choose an scFv that target melanoma as taught by Chen with a reasonable expectation of success. The ordinary skilled artisan would have been motivated to do so not only because Ashley explicitly cites the prior art of Chen for targeted delivery, but also because Chen teaches the scFv targeted the nanoparticles to tumor metastasis in vivo (Introduction, last para., see Figs. 4 & 6). Hence, the claimed invention as a whole was prima facie obvious in the absence of evidence to the contrary. Claims 43-46, and 56-59 are rejected under 35 U.S.C. 103 as being unpatentable over Stephan & Irvine (Nano Today, 2011, 6:309-325, published 06/01/2011, see IDS filed 5/06/2025), in view of Orcutt et al., (Nucl Med Biol, 2011, 38:223-233, see IDS filed 5/06/2025), and Irvine et al., (US 2011/0229556, filed 3/21/2011, published 9/22/2011, see IDS filed 5/06/2025) [AltContent: textbox ([img-media_image2.png])]Stephan and Irvine review synthetic nanocarrier to enhance the function of therapeutic cells. Specifically in regard to claims 43(i)/(ii), as well as claims 44-46, Stephan et al. teach a lipid-based nanocarrier with a CD8 antibody extending from its surface (see Fig. 2f, adjacent). Stephan explains that this modification allows specific uptake of the nanoparticle in CD8 expressing T cells as a result of receptor-induced endocytosis (p. 10, 1st para, and see figure supra). In regard to the scFv domain of the CD8 antibody as per claim 43(ii), Stephan teaches high-affinity antibody fragments can also be used and specifically cites the work of Orcutt et al., 2011 (p. 14, last para.) Orcutt et al., teaches an immunotherapy antibody reduced to a single chain variable fragment (scFv) and then further optimized by affinity maturation (Abstract, Materials & Methods, pgs. 6-7). Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was filed to prepare the antibody-target nanoparticle as taught by Stephan, and to substitute the full CD8 antibody for the scFV as taught by Orcutt with a reasonable expectation of success. The ordinary skilled artisan would have been motivated to do so as taught by Orcutt because the scFv is the minimum portion of the antibody necessary for antigen recognition and can be easily optimized and produced recombinantly unlike full length antibodies (p. 3, 1st para. p. 8, last para.). However, although Stephan and Irvine teach the use of lipid-based nanoparticles for the delivery of cargo to the human T cells (see Fig. 2f from Stephan), they are silent with respect to a (iii) a lipid-based nanoparticle with a porous core comprising a nucleic acid. Nevertheless, Irvine goes on to patent in Irvine et al. (2011) lipid-coated nanoparticles with a porous core for the delivery of agents such as a nucleic acid to immune cells ([0107, 0111], Fig. 1). Specifically, Irvine teaches a lipid coated nanoparticle comprising a PLGA core ([0013-0116, 0060-0064]), wherein the active agent is encapsulated within the core ([0060-0064, 0106-0107], Fig. 1). Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was filed to prepare the lipid-based nanoparticle as taught by Stephan and Irivine, and combine a PLGA core with encapsulated nucleic acids as taught by Irvine with a reasonable expectation of success. The ordinary skilled artisan would have been motivated to do so as taught by Irvine (2011) because PLGA core both protects the encapsulated agents from degradation and is biodegradable [0014, 0056, 0080]. In regard to choosing to encapsulate a nucleic acid as the active agent, Stephan teaches that the genetic engineering of cells is well established as a robust and highly versatile methodology for introducing specific surface proteins to modulate cell function (p. 3, 2nd para.). In regard to claim 56, as shown supra, the nanocarrier is spherical. In regard to claims 57-59, as stated supra, Stephan teaches the internalization of nanoparticles coated with anti-CD8 by primary T cells, which would have been obvious to perform in a sterile pharmaceutically acceptable carrier. Irvine goes on to explain that the after synthesizing the porous nanocarriers they are stored in an aqueous buffer [0106], which is encompasses Applicant’s broad definition of pharmaceutically acceptable carrier (see [0140] of Applicant’s disclosure). Note that in regard to claim 58, intravenous delivery is the intended use of the claimed composition and formulation in a sterile buffer would be meet the structural requirements for intravenous delivery. Hence, the claimed invention as a whole was prima facie obvious in the absence of evidence to the contrary. Claims 47-48 are rejected under 35 U.S.C. 103 as being unpatentable over Stephan & Irvine (Nano Today, 2011, 6:309-325), in view of Orcutt et al., (Nucl Med Biol, 2011, 38:223-233), and Irvine et al., (US 2011/0229556, filed 3/21/2011, published 9/22/2011), as applied to claim 43, in further view of Sharma et al. (Mol Ther NA, 2013,(2)e74) As discussed previously, Stephan et al. suggest a synthetic carrier for transfecting T cells comprising (i) a lipid coated porous nanoparticle, (ii) a CD8 ScFv extending from the surface of the nanocarrier, (iii) a polynucleotide encapsulated in the core of the nanocarrier. However, Stephan et al. are silent with respect to the nucleic acid agent being a minicircle encoding a hyperactive transposase. Sharma teaches a DNA minicircles comprising the hyperactive transposase SB100X (Abstract, Results, p.2-3, see Fig. 1). Accordingly, it would have been prima facie obvious to one of ordinary skill in the art at the time of filing to prepare the nanocarrier comprising a nucleic acid for genetically modifying T cells as suggested by Stephan et al., and choose a minicircle plasmid encoding a hyperactive transposase as taught by Sharma with a reasonable expectation of success. The ordinary skilled artisan would have been motivated to do so as taught by Sharma because DNA transposition from DNA minicircles show great promise in therapeutic gene transfer in primary human T cells (Abstract). Hence, the claimed invention as a whole was prima facie obvious in the absence of evidence to the contrary. Claims 49-51 are rejected under 35 U.S.C. 103 as being unpatentable over Stephan & Irvine (Nano Today, 2011, 6:309-325), in view of Orcutt et al., (Nucl Med Biol, 2011, 38:223-233), and Irvine et al., (US 2011/0229556, filed 3/21/2011, published 9/22/2011), as applied to claim 43, in further view of June et al., (WO2012/079000, see IDS filed 5/06/2025) As discussed previously, Stephan et al. suggest a synthetic carrier for transfecting T cells comprising (i) a lipid coated porous nanoparticle, (ii) a CD8 ScFv extending from the surface of the nanocarrier, (iii) a polynucleotide encapsulated in the core of the nanocarrier. However, although Stephan et al. teaches that tumor-specific effector T cells show tremendous therapeutic potential (p. 2, 1st para.), they are silent with respect to the nucleic acid agent encoding a CAR. June teaches of transfecting T cells to overexpress a chimeric antigen receptor (CAR) in order to treat cancer (see Abstract). Specifically, June et al., teaches a liposome-based nanocarrier in order to transfect said T cells comprising (iii) a polynucleotide encoding CAR that is encapsulated by the nanocarrier (p. 2, Summary of Invention; p. 37, last para, p. 38, 1st para). Furthermore, June et al., teach that the T cells of interest to be transfected are CD8+ (p. 40, line 13, p. 41, line 13). In regard to claims 50 and 51, June teaches the CAR targets a tumor antigen such as CD19 (p. 56, Example 1). Accordingly, it would have been prima facie obvious to one of ordinary skill in the art at the time of filing to prepare the nanocarrier comprising a nucleic acid for genetically modifying T cells as suggested by Stephan et al., and choose a nucleic acid encoding an anti-CD19 CAR as taught by June with a reasonable expectation of success. The ordinary skilled artisan would have been motivated to do so as taught by June because CAR T cells can be engineered to target any tumor or interest. 28, 2nd para.), and were shown to have a potent non-cross resistant clinical activity (p. 56, Example 1). Furthermore, in regard to choosing CD19 as the tumor antigen, June teaches that CD19 is restricted in expression on the surface of malignant cells and is widely accepted target to safely test CARs (p. 1, 3rd para., p. 82, lines 7-8). Hence, the claimed invention as a whole was prima facie obvious in the absence of evidence to the contrary. Claim 52 is rejected under 35 U.S.C. 103 as being unpatentable over Stephan & Irvine (Nano Today, 2011, 6:309-325), in view of Orcutt et al., (Nucl Med Biol, 2011, 38:223-233), and Irvine et al., (US 2011/0229556, filed 3/21/2011, published 9/22/2011), as applied to claim 43, in further view of Voss et al., (US2006/0166314, filed 9/24/2003, published 7/27/2006) As discussed previously, Stephan et al. suggest a synthetic carrier for transfecting T cells comprising (i) a lipid coated porous nanoparticle, (ii) a CD8 ScFv extending from the surface of the nanocarrier, (iii) a polynucleotide encapsulated in the core of the nanocarrier. However, although Stephan et al. teaches that tumor-specific effector T cells show tremendous therapeutic potential (p. 2, 1st para.), they are silent with respect to the nucleic acid agent encoding a TCR. Voss teaches of transfecting T cells to overexpress a TCR in order to treat cancer (see Abstract). Specifically, Voss et al., teaches a liposome-based nanocarrier in order to transfect said T cells comprising (iii) a polynucleotide encoding TCR ([0021, 0065-0066], see Claim 5 of Voss). Furthermore, Voss et al., teach that the T cells of interest to be transfected are CD8+ ([0069, 0071]). Accordingly, it would have been prima facie obvious to one of ordinary skill in the art at the time of filing to prepare the nanocarrier comprising a nucleic acid for genetically modifying T cells as suggested by Stephan et al., and choose a nucleic acid encoding a TCR as taught by Voss with a reasonable expectation of success. The ordinary skilled artisan would have been motivated to do so as taught by Voss because tumor antigen-specific TCRs can be used to make highly effective T cells that are able to specifically recognized and lyse human tumor cells [0006-0007]. Hence, the claimed invention as a whole was prima facie obvious in the absence of evidence to the contrary. Claims 53-55 are rejected under 35 U.S.C. 103 as being unpatentable over Stephan & Irvine (Nano Today, 2011, 6:309-325), in view of Orcutt et al., (Nucl Med Biol, 2011, 38:223-233), and Irvine et al., (US 2011/0229556, filed 3/21/2011, published 9/22/2011), as applied to claim 43, in further view of Woodle et al., (US2003/0166601, see IDS filed 5/06/2025) As discussed previously, Stephan et al. suggest a synthetic carrier for transfecting T cells comprising (i) a lipid coated porous nanoparticle, (ii) a CD8 ScFv extending from the surface of the nanocarrier, (iii) a polynucleotide encapsulated in the core of the nanocarrier. However, Stephan et al. are silent with respect to the nanocarrier further comprising (i) an endosomal releasing agent on the surface of the nanoparticle, and (ii) a NLS within the nanoparticle. Woodle teaches of nanocarrier compositions for gene therapy purposes (see Abstract). Specifically in regard to claim 47, Woodle teaches that the nanoparticle comprise (i) an endosomal releasing agent on the surface of the nanoparticle ([0029], [0169], [0182], see claim 19), and (ii) a NLS conjugated to the nucleic acid within the nanoparticle ([0085], Figs. 1 & 10A, see claim 19). In regard to claim 48, Woodle teaches the endosomal releasing agent is an HIV tat peptide [0169], which corresponds to instant claim’s SEQ ID NO:32 (see SCORE report 8/6/2018, rag file, results 1-5). In regard to claim 49, Woodle teaches the NLS comprising the amino acid sequence of PKKKRKV (see Example 49, [0479]), which corresponds to instant claim’s SEQ ID NO: 51. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was filed to prepare the DNA encapsulated nanoparticle as taught by Stephan et al. and further combine (i) an endosomal releasing agent on the surface of the nanoparticle, and (ii) a NLS conjugated to the nucleic acid within the nanoparticle as taught by Woodle with a reasonable expectation of success. The ordinary skilled artisan would have been motivated to do so as taught by Woodle because (i) an endosomal releasing agent on the surface of the nanoparticle allows escape of the particle into the target cell's cytoplasm [0169], and (ii) a NLS conjugated to the DNA allows transport of the DNA to the nucleus for improved transcription [0085, 0164]. Hence, the claimed invention as a whole was prima facie obvious in the absence of evidence to the contrary. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). Claims 43-47, 49-51, 53-60 are rejected on the grounds of nonstatutory double patenting over claims 1-16 of U.S. Patent No. 10,392,446 (Stephan, Patented 8/27/2019). The subject matter claimed in the instant application is disclosed in the referenced patent as follows: the method for treating cancer comprising infusing a synthetic nanocarrier of cited patent makes obvious the nanocarrier of instant application. It is clear that all the elements of the cited patent claims are to be found in instant claims. The difference between the cited patent claims and the cited patent claims are the intended use of instant claims lies, and there is no unobvious step in the process (i.e., infusion). Since the instant application claims are obvious over cited patent claims, said claims are not patentably distinct. Claim 48 is rejected on the grounds of nonstatutory double patenting over claims 1-16 of U.S. Patent No. 10,392,446 (Stephan, Patented 8/27/2019), in view of Sharma et al. (Mol Ther NA, 2013,(2)e74). The subject matter claimed in the instant application is disclosed in the referenced patent as follows: the method for treating cancer comprising infusing a synthetic nanocarrier of cited patent makes obvious the nanocarrier of instant application. However, cited patent claims are are silent with respect to the nucleic acid agent being a minicircle encoding a hyperactive transposase. Sharma teaches a DNA minicircles comprising the hyperactive transposase SB100X (Abstract, Results, p.2-3, see Fig. 1). Accordingly, it would have been prima facie obvious to one of ordinary skill in the art at the time of filing to prepare the nanocarrier comprising a nucleic acid for genetically modifying T cells as a claimed by cited patent and choose a minicircle plasmid encoding a hyperactive transposase as taught by Sharma with a reasonable expectation of success. The ordinary skilled artisan would have been motivated to do so as taught by Sharma because DNA transposition from DNA minicircles show great promise in therapeutic gene transfer in primary human T cells (Abstract). Since the instant application claims are obvious over cited patent claims in view of Sharma, said claims are not patentably distinct. Conclusion No claims are allowed. Examiner Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to ARTHUR S LEONARD whose telephone number is (571)270-3073. The examiner can normally be reached on Mon-Fri 9am-5pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Doug Schultz can be reached on 571-272-0763. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ARTHUR S LEONARD/Examiner, Art Unit 1631
Read full office action

Prosecution Timeline

Feb 26, 2025
Application Filed
Oct 28, 2026
Non-Final Rejection mailed — §102, §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766097
TREATMENT OF CNS LYMPHOMA AND SYSTEMIC LYMPHOMA WITH INTRACEREBROVENTRICULARLY ADMINISTERED CD19 CAR
6y 5m to grant Granted Oct 20, 2026
Patent 12760085
ENHANCED T-CELL RECEPTOR STAR AND APPLICATION THEREOF
3y 6m to grant Granted Oct 13, 2026
Patent 12760274
COMPOSITIONS AND METHODS OF STIMULATING AND EXPANDING T CELLS
4y 1m to grant Granted Oct 13, 2026
Patent 12734250
MODIFIED UBE3A GENE FOR A GENE THERAPY APPROACH FOR ANGELMAN SYNDROME
3y 8m to grant Granted Sep 15, 2026
Patent 12721327
Rat models for CMT2A that develop a progressive neuropathy
2y 11m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
50%
Grant Probability
99%
With Interview (+50.4%)
3y 5m (~1y 9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 523 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month